Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340854 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
A Phase 3 study of Diabetes Type 2, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
- 20
- Study locations
NCT06340854 is a Phase 3 study of Diabetes Type 2 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 429 participants, below the 722-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06340854, a Phase 3 study of Diabetes Type 2, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.
Conditions Studied
Interventions
- DRUG Insulin icodec
- DRUG Insulin glargine
Study Locations (20)
Texas
- Amarillo Medical Specialists - Amarillo
- Velocity Clinical Res-Dallas - Dallas
- Victorium Clinical Research - Houston
- PlanIt Research, PLLC - Houston
California
- Advanced Investigative Medicine, Inc. - Hawthorne
- Scripps Whittier Diabetes Inst - La Jolla
- Clinical Trials Research - Lincoln
Florida
- Northeast Research Institute of Florida - Fleming Island
- South Broward Research LLC - Miramar
North Carolina
- PharmQuest Life Sciences LLC - Greensboro
- Accellacare Wilmington - Wilmington
Georgia
- Endo Res Solutions Inc - Roswell
Kansas
- Cotton-Oneill Diabetes and End - Topeka
Minnesota
- International Diabetes Center - Minneapolis
Missouri
- Jefferson City Medical Group, PC - Jefferson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06340854
The ClinicalTrials.gov registry entry for NCT06340854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 429 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 722-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (41% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Insulin icodec is the first listed.
NCT06340854 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06340854 about?
NCT06340854 is a clinical study titled "A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes". This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is de...
What is the current status of trial NCT06340854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2024-04-19. Estimated completion is 2025-06-13.
What conditions does trial NCT06340854 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06340854?
The interventions under investigation include: Insulin icodec (DRUG), Insulin glargine (DRUG).
Who is sponsoring clinical trial NCT06340854?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340854 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
COMPLETED · Phase 3
-
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
COMPLETED · Phase 3
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.